Стандартная индукционная терапия АНЦА-ассоциированных системных васкулитов: мифы и реальность
- Авторы: Бекетова Т.В1
-
Учреждения:
- ФГБНУ НИИР им. В.А. Насоновой
- Выпуск: № 7 (2015)
- Страницы: 7-13
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/287879
- ID: 287879
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Список литературы
- Jennette J., Falk R., Bacon P., Basu N., Cid M.C., Ferrario F., Flores-Suarez L.F., Gross W.L., Guillevin L., Hagen E.C., Hoffman G.S., Jayne D.R., Kallenberg C.G., Lamprecht P., Langford C.A., Luqmani R.A., Mahr A.D., Matteson E.L., Merkel P.A., Ozen S., Pusey C.D., Rasmussen N., Rees A.J., Scott D.G., Specks U., Stone J.H., Takahashi K., Watts R.A. 2012. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2012;65:1-11.
- Walton E. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br. Med. J. 1958;2:265-70.
- Lane S., Watts R., Shepstone L., Scott D. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97-111.
- Mohammad A., Jacobsson L., Westman K., Sturfelt, G., Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48(12):1560-65.
- Feder G., Eccles M., Grol R., Griffiths C., Grimshaw J. Clinical guidelines: using clinical guidelines. BMJ. 1999;318(7185):728-30.
- Ollenschlager G., Kirchner H., Fiene М. Leitlinien in der Medizin- scheitern sie an der praktischen Umsetzung? Der Internist. 2001;42(4): 473-83.
- Ntatsaki E., Carruthers D.,Chakravarty K., D'CruzD., Harper L., Jayne D., Luqmani R., Mills J., Mooney J., Venning M., Watts R.A.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014; 53(12):2306-09.
- Guerry M., Brogan P., Bruce I., D'Cruz D.P., Harper L., Luqmani R., Pusey C.D., Salama A.D., Scott D.G., Savage C.O., Watts R.A., Jayne D.R. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody- associated vasculitis. Rheumatology. 2012;51(4): 634-43.
- Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Монография под ред. Насонова Е.Л. М., 2012. 343 с.
- Мухин Н.А., Новиков П.И., Моисеев С.В. и др. Оценка краткосрочной эффективности и безопасности биологических препаратов при различных ревматических заболеваниях -опыт многопрофильного терапевтического стационара. Научно-практическая ревматология. 2013;51(2):138-44.
- Бекетова Т.В., Насонов Е.Л., Александрова Е.Н. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (Ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;2:147-59.
- Luqmani R., Bacon P., Moots R., Janssen B., Pali A., Emery P., Savage C., Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-78.
- Guiiievin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumeiin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vascuiitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90:19-27.
- Bhamra K., Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr. Rheumatol. Rep. 2012;14(6):494-500.
- Семенкова Е.Н. Системные некротизирующие васкулиты. М., 2001. 96 с.
- Бекетова Т.В. Гранулематоз с полиангиитом, патогенетически связанный с антинейтрофильными цитоплазматическими антителами: особенности клинического течения. Научно-практическая ревматология. 2012;6:19-28.
- Robson J., Doll H., Suppiah R., Flossmann O., Harper L., Hoglund P., Jayne D., Mahr A., Westman K., Luqmani R. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471-81.
- Harper L., Morgan M., Walsh M., Hoglund P., Westman K., Flossmann O., Tesar V., Vanhille P., de Groot K., Luqmani R., Flores-Suarez L.F., Watts R., Pusey C., Bruchfeld A., Rasmussen N., Blockmans D., Savage C.O., Jayne D.; EUVAS investigators.Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum. Dis. 2012;71: 955-60.
- Walsh M., Merkel P., Mahr A., Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166-73.
- Behrens T., Goodwin J. Glucocorticoids. In: Arthritis and allied conditions. A text-book of rheumatology. Ed. D.J. McCarry. Lea&Febiger. Philad.London, 1989. P. 604-21.
- Fauci A., Haynes B., Katz P., Wolff S. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 1983;98:76-85.
- National Chemotherapy Advisory Group. Chemotherapy Services in England: Ensuring Quality and Safety. London, UK: D.o. Health, 2009.
- Makar V., Logani M., Szabo I., Ziskin M. Effect of millimeter waves on cyclophosphamide induced suppression of T cell functions. Bioelectromagnetics. 2003;24(5):356-65.
- de Groot K., Harper L., Jayne D., Flores Suarez L.F., Gregorini G., Gross W.L., Luqmani R., Pusey C.D., Rasmussen N., Sinico R.A., Tesar V., Vanhille P., Westman K., Savage C.O.; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 2009;150:670-80.
- Faurschou M., Westman K., Rasmussen N., de Groot К., Flossmann O., Hoglund P., Jayne D.R. Brief report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3472-77.
- Jones R., Walsh M. A randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: MYCYC [abstract]. J. Am. Soc. Nephrol. 2012;23:3B.
- Pagnoux C., Hogan S., Chin H., Jennette J.C., Falk R.J., Guillevin L., Nachman P.H. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthr.Rheum. 2008;58:2908-18.
- Monach P., Arnold L., Merkel P. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62:9-21.
- Fauci A., Dale D., Balow J. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann. Intern. Med. 1976;84(3):304-15.
- Соловьев С.К., Иванова М.М., СперанскийА.И., Насонов Е.Л. Внутривенное введение ударных доз метилпреднизолона (пульс-терапия) при люпус-нефрите. Тер. Архив. 1983;7:114-19.
- Bolton W., Sturgill B. Methylprednisolone therapy for acute crescentic rapidly progres sive glomerulonephritis. Am. J. Nephrol. 1989; 9:368-75.
- Tesfa D., Ajeganova S., Hagglund H., Sander B., Fadeel B., Hafström I., Palmblad J. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14.
- Wendt M., Gunnarson I., Bratt J., Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: A case series of 16 patients. Scand. J. Rheumatol. 2012;41:116-19.
- Pullerits R., Ljevakt M., Vikgren J., Bokarewa M. Off-trial evaluation of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre. Scand. J. Immunol. 2012;76:411-20.
- Bosch X., Guilabert A., Espinosa G., Mirapeix E. Treatment of antineutrophil cytoplasmic antibody- associated vasculitis. JAMA. 2007;298:655-69.
- Stegeman C., Tervaert J., Sluiter W., Manson W.L., de Jong P.E., Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med. 1994;120:12-7.
- Le Guenno G., Mahr A., Pagnoux C., Dhote R., Guillevin L.; French Vasculitis Study Group. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthr. Rheum. 2011;63:1435-45.
- Knight A., Askling J., Granath F., Sparen P., Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann. Rheum. Dis. 2004;63:1307-11.
- Александров Н.Н., Савченко Н.Е., Фрадкин С.З. и др. Применение гипертермии и гипергликемии при лечении злокачественных опухолей. М., 1980. 256 с.
- Honjo I., Suou T., Hirayama C. Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res. Commun. Chem. Pathol. Pharmacol. 1988;61(2):149-65.
- Haubitz M., Bohnenstengel F., Brunkhorst R., Schwab M., Hofmann U., Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 2002;61(4):1495-501.
- Perry J., Fleming R., Rocco M., Petros W.P., Bleyer A.J., Radford J.E. Jr., Powell B.L., Hurd D.D. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant. 1999;23(8):839-42.
- Bischoff M., Blau W., Wagner T., Wagenmann W., Dörner O., Basara N., Fauser A.A. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow trans plantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant. 1998;22(6):591-93.
- Bagley C., Bostick F., DeVita V. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973;33(2):226-33.
- Juma F., Rogers H., Trounce J. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J. Clin. Pharmacol. 1981;19(6):443-51.
- Mouridsen H., Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol. Toxicol. (Copenh). 1975; 36(Suppl. 5):409-14.
- Humphrey R., Kvols L. The influence of renal insufficiency on cyclophosphamide-induced hematopoietic depression and recovery. Proc. Am. Assoc. Cancer Res. 1974;15:84.
- Bramwell V., Calvert R., Edwards G., Scarffe H., Crowther D. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother. Pharmacol. 1979;3(4):253-59.
- Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys Editors: Golightly L., Teitelbaum I., Kiser T. Springer Science & Business Media, New York, 2013. 742 p.
- Moran S., Little M. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 2014; 26(1):37-41.
Дополнительные файлы
![](/img/style/loading.gif)